Filtered By:
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 20131 results found since Jan 2013.
Targeted therapies for glioblastoma treatment
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.01. Epub 2023 Aug 30.ABSTRACTGlioblastoma, the most common and aggressive type of brain tumor in adults, poses significant challenges in terms of treatment. Conventional approaches including surgery, chemotherapy, and radiotherapy have yielded limited success, with a median survival of approximately 15 months. However, extensive research into the biology of glioblastoma has identified molecular targets that can be exploited by newly developed drugs, leading to the emergence of precise personalized therapies. Several innovative treatment strategies are currently ...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: A Smolarska I Pruszynska W Wasylko K Godlewska M Markowska A Rybak J Botther P Kucharzewska J Nowakowska J Szeliga M Kubiak M Gorczak M Krol Source Type: research
Naringin modulates microglial polarization through the PPAR- γ/NF-κB signaling pathway to promote functional recovery following spinal cord injury
CONCLUSION: Nar promotes functional recovery by regulating microglial polarization and inhibiting the inflammatory response in SCI, and its mechanism may be related to the PPAR-γ/NF-κB signaling pathway activity.PMID:37661010 | DOI:10.1016/j.brainres.2023.148563
Source: Brain Research - September 3, 2023 Category: Neurology Authors: Bo Li Xi-Fan Mei Source Type: research
Targeted therapies for glioblastoma treatment
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.01. Epub 2023 Aug 30.ABSTRACTGlioblastoma, the most common and aggressive type of brain tumor in adults, poses significant challenges in terms of treatment. Conventional approaches including surgery, chemotherapy, and radiotherapy have yielded limited success, with a median survival of approximately 15 months. However, extensive research into the biology of glioblastoma has identified molecular targets that can be exploited by newly developed drugs, leading to the emergence of precise personalized therapies. Several innovative treatment strategies are currently ...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: A Smolarska I Pruszynska W Wasylko K Godlewska M Markowska A Rybak J Botther P Kucharzewska J Nowakowska J Szeliga M Kubiak M Gorczak M Krol Source Type: research
Naringin modulates microglial polarization through the PPAR- γ/NF-κB signaling pathway to promote functional recovery following spinal cord injury
CONCLUSION: Nar promotes functional recovery by regulating microglial polarization and inhibiting the inflammatory response in SCI, and its mechanism may be related to the PPAR-γ/NF-κB signaling pathway activity.PMID:37661010 | DOI:10.1016/j.brainres.2023.148563
Source: Brain Research - September 3, 2023 Category: Neurology Authors: Bo Li Xi-Fan Mei Source Type: research
Targeted therapies for glioblastoma treatment
J Physiol Pharmacol. 2023 Jun;74(3). doi: 10.26402/jpp.2023.3.01. Epub 2023 Aug 30.ABSTRACTGlioblastoma, the most common and aggressive type of brain tumor in adults, poses significant challenges in terms of treatment. Conventional approaches including surgery, chemotherapy, and radiotherapy have yielded limited success, with a median survival of approximately 15 months. However, extensive research into the biology of glioblastoma has identified molecular targets that can be exploited by newly developed drugs, leading to the emergence of precise personalized therapies. Several innovative treatment strategies are currently ...
Source: J Physiol Pharmacol - September 3, 2023 Category: Drugs & Pharmacology Authors: A Smolarska I Pruszynska W Wasylko K Godlewska M Markowska A Rybak J Botther P Kucharzewska J Nowakowska J Szeliga M Kubiak M Gorczak M Krol Source Type: research
Influence of focused ultrasound on locoregional drug delivery to the brain: Potential implications for brain tumor therapy
CONCLUSION: 1. Based on our findings, IV delivery coupled with FUS-BBBO is a more efficient means for delivery to deep targets (i.e. striatal-thalamic region) within a predefined spatial conformation compared to IT administration. 2. FUS-BBBO increases the volume of distribution (Vd) of dye after CED administration, but results in a shorter time of residence. Whether this finding is reproducible with other classes of agents (e.g., cytotoxic agents, antibodies, viral particles, cellular therapies) needs to be studied.PMID:37659767 | DOI:10.1016/j.jconrel.2023.08.060
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Rafael Uribe Cardenas Madeline Laramee Nadia Dahmane Mark Souweidane Brice Martin Source Type: research
